Advertisement

Pediatric Vasculitis

  • Anne H. Rowley
  • Seza Ozen
  • Robert P. Sundel
  • Frank T. Saulsbury

Abstract

Based on surverys of providers, vasculitis in children appears to have an incidence of about 50 cases per 100,000 children per year. Only HSP and KD are more common in children than in adults, with each one affecting at least 10–20/100,000 pediatric patients per year. Takayasu arteritis and ANCA-positive vasculiti-des, on the other hand, strike approximately one child in a million each year. Differences between adult and pediatric vasculitides are generally subtle, though they may have important implications. Since these conditions are so rare in the pediatric age group, diagnosis may be significantly delayed, leading to more disease-related damage at the time therapy is initiated. In addition, unlike adults, children may suffer irreversible effects on their physical and mental development both from the disease and from the medications used to treat it. On the other hand, children tend to have fewer comor-bidities and they are therefore more tolerant of potentially toxic therapies. This often results in better outcomes for children than adults, especially in conditions like Takayasu arteritis and PAN. Kawasaki disease (KD) has replaced acute rheumatic fever as the leading cause of acquired heart disease among children in developed nations. Since IVIG became the standard treatment for KD in 1986, the mortality rate of the disease has decreased from 1–2% to <0.1%, and the incidence of coronary artery aneu-rysms has decreased by 75%. Henoch-Schonlein purpura, also known as anaphylac-tic purpura, is a benign condition in the vast majority of affected children. Nonetheless, in rare cases, children affected by HSP may develop hypertension (especially during pregnancy) or renal failure long after the acute syndrome has resolved. One-third or more of children with PAN have the cutaneous form, largely limited to skin and joint involvement. While mortality is rare, aggressive control of the systemic inflammation and end-organ involvement is nonetheless needed if significant long-term morbidity is to be avoided.

Keywords

Respiratory Syncytial Virus Kawasaki Disease Familial Mediterranean Fever Takayasu Arteritis Cutaneous Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Allen AC, Willis FR, Beattie TJ, et al. Abnormal IgA glycosylation in Henoch–Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant. 1998;13:930–4PubMedCrossRefGoogle Scholar
  2. Amano S, Hazama F, Kubagawa H, et al. General pathology of Kawasaki disease. Acta Pathol Jpn. 1980;30(5):681–94PubMedGoogle Scholar
  3. Anderson MS, Burns J, Treadwell TA, et al. Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease. Pediatr Infect Dis J. 2001;20(7):698–702PubMedCrossRefGoogle Scholar
  4. Bártfai Z, Gaede KI, Russell KA, et al. Different gender-associated genotype risks of Wegener's granulomatosis and microscopic poly-angiitis. Clin Immunol. 2003;109(3):330–7PubMedCrossRefGoogle Scholar
  5. Binstadt BA, Levine JC, Nigrovic PA, et al. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics 2005;116:e89–93PubMedCrossRefGoogle Scholar
  6. Birchmore D, Sweeney C, Choudhury D, et al. IgA multiple myeloma presenting as HSP/Polyarteritis nodosa overlap. Arthritis Rheum. 1996;39:698–703PubMedCrossRefGoogle Scholar
  7. Burns JC, Wiggins JW, Toews WH, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr. 1986;109:759–63PubMedCrossRefGoogle Scholar
  8. Burns JC, Mason WH, Glode MP, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr. 1991;118:680–6PubMedCrossRefGoogle Scholar
  9. Burns JC, Shimizu C, Shike H, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun. 2005;6(5):438–44PubMedCrossRefGoogle Scholar
  10. Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35(5):913–19PubMedGoogle Scholar
  11. Centers for Disease Control. Haemophilus influenzae invasive disease among children age <5 years–California, 1990–1996. MMWR. 1998;47:737–40Google Scholar
  12. Choong CK, Beasley SW. Intra-abdominal manifestations of Henoch-Schönlein purpura. J Paediatr Child Health. 1998;34:405–9PubMedCrossRefGoogle Scholar
  13. Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clini-copathological study of 79 cases. Br J Dermatol. 1997;136:706–13PubMedCrossRefGoogle Scholar
  14. Dengler LD, Capparelli E V, Bastian JF, et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998;17:478–81PubMedCrossRefGoogle Scholar
  15. Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr. 2004;163:425–34PubMedCrossRefGoogle Scholar
  16. Golding RL, Perri G, Cremin BJ. The arteriographic manifestations of Takayasu's arteritis in children. Pediatr Radiol. 1977;5:224–30PubMedCrossRefGoogle Scholar
  17. Goldstein AR, White RHR, Akuse R, et al Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 1992;339:280–2PubMedCrossRefGoogle Scholar
  18. Holman RC, Belay ED, Curns AT, et al. Kawasaki syndrome hospital-izations among children in the United States, 1988–1997. Pediatrics 2003;111:e448CrossRefGoogle Scholar
  19. Jurado RL. Why shouldn't we determine the erythrocyte sedimentation rate? Clin Infect Dis. 2001;33:548–9PubMedCrossRefGoogle Scholar
  20. Kumar L, Thapa BR, Sarkar B, Walia BN. Benign cutaneous PAN in children below 10 years of age: a clinical experience. Ann Rheum Dis. 1995;54:134–6PubMedCrossRefGoogle Scholar
  21. Landing BH, Larson EJ. Are infantile periarteritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from North America with patients from Hawaii and Japan. Pediatrics 1977;59:651–62PubMedGoogle Scholar
  22. Momenah T, Sanatani S, Potts J, et al. Kawasaki disease in the older child. Pediatrics 1998;e102(1):e7CrossRefGoogle Scholar
  23. Muta H, Ishii M, Sakaue T, et al Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 2004;114:751–4PubMedCrossRefGoogle Scholar
  24. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch–Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916–20PubMedCrossRefGoogle Scholar
  25. Newburger J, et al Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, Am Heart Assoc Pediatr. 2004a;114:1708–33Google Scholar
  26. Newburger JW, Sanders SP, Burns JC, et al Left ventricular contractility and function in Kawasaki syndrome. Circulation 1989;79:1237–46PubMedCrossRefGoogle Scholar
  27. Newburger JW, Takahashi M, Gerber MA, et al Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation 2004a;110:2747–71CrossRefGoogle Scholar
  28. Niwa K, Aotsuka H, Hamada H, et al. Thrombocytopenia: a risk factor for acute myocardial infarction during the acute phase of Kawasaki Disease. Coron Artery Dis. 1995;6(11):857–64PubMedGoogle Scholar
  29. Ozdogan H, Arisoy N, Kasapcapur O, et al. Vasculitis in familial Mediterranean fever. J Rheumatol. 1997;24:323–7PubMedGoogle Scholar
  30. Ozen S, Bakkaloglu A, Yilmaz E, Duzova A, Balci B, Topaloglu R, Besbas N. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol. 2003;30(9):2014–8PubMedGoogle Scholar
  31. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517–22PubMedCrossRefGoogle Scholar
  32. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41PubMedCrossRefGoogle Scholar
  33. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corti-costeroids followed by methotrexate. J Pediatr. 2007;150:72–6PubMedCrossRefGoogle Scholar
  34. Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch–Schönlein purpura: a retrospective cohort study. Lancet 2002;360:666–70PubMedCrossRefGoogle Scholar
  35. Ronkainen J, Ala-Houhala M, Huttunen NP, et al. Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clin Nephrol. 2003;60:80–4PubMedGoogle Scholar
  36. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149:241–7PubMedCrossRefGoogle Scholar
  37. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr. 1995;126:524–49PubMedCrossRefGoogle Scholar
  38. Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr. 1993;122(1):26–31PubMedCrossRefGoogle Scholar
  39. Saulsbury FT. Corticosteroid therapy does not prevent nephritis in Henoch–Schönlein purpura. Pediatr Nephrol. 1993;7:69–71PubMedCrossRefGoogle Scholar
  40. Saulsbury FT. Alterations in the O-linked glycosylation of IgA1 in children with Henoch-Schönlein purpura. J Rheumatol. 1997;24:2246–9PubMedGoogle Scholar
  41. Saulsbury FT. Henoch-Schönlein purpura in children: report of 100 patients and review of the literature. Medicine 1999;78:395–409PubMedCrossRefGoogle Scholar
  42. Saulsbury FT. Henoch-Schönlein purpura. Curr Opin Rheumatol. 2001;13:35–40PubMedCrossRefGoogle Scholar
  43. Seo P, Luqmani R, Flossmann O, et al. The future damage assessment in vasculitis. J Rheumatol. 2007;34:1357–71PubMedGoogle Scholar
  44. Spriewald BM, Witzke O, Wassmuth R, et al. Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis. 2005;64:457–61PubMedCrossRefGoogle Scholar
  45. Stamos JK, Corydon K, Donaldson J, Shulman ST. Lymphadenitis as the dominant manifestation of Kawasaki disease. Pediatrics 1994;93(3):525–8PubMedGoogle Scholar
  46. Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr. 2000;137:250–2PubMedCrossRefGoogle Scholar
  47. Stone JH, Nousari HC. Essential cutaneous vasculitis: everything a rheumatologist needs to know about vasculitis of the skin. Curr Opin Rheumatol. 2001;13:23–34PubMedCrossRefGoogle Scholar
  48. Tanaka N, Sekimoto K, Naoe S. Kawasaki disease. Relationship with infantile periarteritis nodosa. Arch Pathol Lab Med. 1976;100:81–6PubMedGoogle Scholar
  49. Trapani S, Micheli A, Grisolia F, et al. Henoch-Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of the literature. Semin Arthritis Rheum. 2005;35:143–53PubMedCrossRefGoogle Scholar
  50. Tse W Y, Cockwell P, Savage CO. Assessment of disease activity in systemic vasculitis. Postgrad Med J. 1998;74:1–6PubMedCrossRefGoogle Scholar
  51. Umezawa T, Saji T, Matsuo N, Odagiri K. Chest X-ray findings in the acute phase of Kawasaki disease. Pediatr Radiol. 1989;20(1–2):48–51PubMedCrossRefGoogle Scholar
  52. van Leeuwen MA, van Rijswijk MH. Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin Rheumatol. 1994;8(3):531–52PubMedCrossRefGoogle Scholar
  53. Wickiser JE, Saulsbury FT. Henoch-Schönlein purpura in a child with hyperimmunoglobulinemia D and periodic fever syndrome. Pediatr Dermatol. 2005;22:138–41PubMedCrossRefGoogle Scholar
  54. Yalçinkaya F, Ozçakar ZB, Kasapçopur O, et al. Prevalence of the MEFV gene mutations in childhood PAN. J Pediatr. 2007;151:675–8PubMedCrossRefGoogle Scholar
  55. Yanagawa H, Nakamura Y, Yashiro M, et al. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics 2001; 107(3):e33PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Anne H. Rowley
    • 1
  • Seza Ozen
    • 2
  • Robert P. Sundel
    • 3
  • Frank T. Saulsbury
    • 4
  1. 1.Department of Microbiology/Immunology Ward 12-140, Pediatrics W-140Northwestern University Medical SchoolChicagoUSA
  2. 2.Department of Pediatric Nephrology and RheumatologyHacettepe University Faculty of MedicineSihhiyeTurkey
  3. 3.Children's Hospital, Harvard Medical SchoolBostonUSA
  4. 4.University of Virginia Medical Center Department of PediatricsCharlottesvilleUSA

Personalised recommendations